M&A Year in Review 2023 brochure - Flipbook - Page 36
36
Life Sciences and Health Care
We advised Beacon Biosignals, a leading computational
neurodiagnostics and electroencephalogram (EEG)
analytics company, on its acquisition of the research
and development business of Dreem SAS, a Paris-based
pioneer in at-home sleep monitoring.
The acquisition sets the stage for clinical trial
assessments at scale via the integration of Dreem’s
hardware
with
Beacon’s
next-generation
EEG
analytics platform.
Lawyers from our restructuring team in Paris led the
transaction, with support from our antitrust practice.
We advised Novartis on its acquisition of Chinook
Therapeutics,
a
clinical-stage
biopharmaceutical
company, for up to US$3.5 billion, including US$300
million of contingent value rights (CVRs).
The transaction expands Novartis’ renal portfolio
with the addition of two late-stage assets to treat rare
kidney diseases.
Lawyers in our Washington, D.C. o昀케ce led the
transaction, with support from our Amsterdam,
London, Los Angeles, New York, Philadelphia,
and San Francisco o昀케ces and our employee
bene昀椀ts, employment, FDA, intellectual property,
litigation, privacy and cybersecurity, real estate, and
tax practices.
We advised Fresenius Kabi, a global health care company,
on the divestment of its plant in Halden, Norway, to HP
Halden Pharma AS, a company of the Prange Group.
The transaction enables Fresenius Kabi to further
execute its Vision 2026 strategy, a comprehensive,
global framework for sustainable growth and cost and
e昀케ciency improvements.
Lawyers in our Frankfurt o昀케ce led the transaction, with
support from our Berlin, Hamburg, and Munich o昀케ces
and our antitrust, employment, 昀椀nance, and regulatory
practices.
We advised Kaiser Foundation Hospitals on its launch
of Risant Health, a newly formed company designed to
expand value-based care in community-based health
systems, and Risant’s 昀椀rst acquisition of Geisinger
Health, a health system.
Risant plans to acquire up to 昀椀ve additional health
systems in the next 昀椀ve years to become a US$30 to
US$35 billion annual revenue company.
Lawyers in our Washington, D.C. and New York o昀케ces
led the transaction, with support from our Denver,
Los Angeles, Miami, and Philadelphia o昀케ces and our
antitrust, employee bene昀椀ts, employment, environment,
health, infrastructure and projects, intellectual property,
privacy and cybersecurity, real estate, and tax practices.
